CD8A and neoplasm: Consequently, this has two aspects: the first is to diminish the capability of natural immune responses to control cancers, and the second is to inhibit immune therapies that work by re-stimulating anti-tumor CD8+ T cytotoxic, such as checkpoint blockades [78].